Loading...

CRDF CARDIFF ONCOLOGY INC Management Changes 8-K Filing

CRDF

CRDF

CARDIFF ONCOLOGY INC

(CRDF)

2026 8-K

Management Changes

Management Changes

Corporate Presentation

Financial Results Update

Leadership Changes

Quarterly Results

Clinical Trial Update

Financial Statements

Financial Results

By-law Amendments

Positive Trial Data

Q2 Financial Results

Earnings Reports

Annual Meeting of Stockholders

Amendment and Stock Options

Earnings Reports

Conference Presentation

Financial Results and Clini...

Regulation FD Disclosure

Financial Results and Certi...

Stock Options Granted

Annual Meeting of Stockholders

Earnings Reports

Regulation FD Disclosure

Earnings Reports

Appointment of Chief Medica...

External Links:

On March 27, 2026, Cardiff Oncology, Inc. announced the separation agreements for CEO Dr. Mark Erlander and CFO James Levine, providing them severance packages totaling $757,238 and $551,740, respectively, along with continued healthcare for 12 months. Dr. Erlander also resigned from the board of directors on the same date.

AI Assistant

CARDIFF ONCOLOGY INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.